Back to results
US 11,442,065 B2Granted
Marker for gastrointestinal tumors
AssigneeRhode Island Hospital
InventorsWentian Yang, Lijun Wang, Douglas C. Moore
Life of this patent
Estimating the term…
Abstract
The invention provides that OSTERIX (a.k.a. SP7) is a marker for gastrointestinal stem cells and that OSTERIX is expressed widely and at elevated levels in human gastrointestinal tumors.
Claims5
A method for selectively treating gastrointestinal cancer in a patient in need thereof, comprising the steps of:
- (a) selecting a patient for treatment with an anticancer agent;
- (b) providing a series of biological samples from the subject over a time period;
- (c) analyzing the series of biological samples to determine the amount of OSTERIX marker in the subject's biological samples;
- (d) determining the change in the amount of OSTERIX marker in the biological samples;
- and
- (e) determining based upon the change whether to initiate or continue the prophylaxis or therapy of gastrointestinal cancer, and
- (f) administering a therapeutically effective amount of an anticancer agent or method to the patient,
- wherein the anticancer agent or method is selected from the group consisting of:
- (i) non-drug treatments selected from the group consisting of Radio Frequency Ablation (RFA) and Hepatic Arterial Chemoembolization (HACE);
- (ii) adjuvant or neoadjuvant therapy selected from the group consisting of imatinib, sunitinib, regorafenib, and avapritinib;
- (iii) EGFR inhibitors selected from the group consisting of cetuximab, panitumumab, and necitumumab;
- (iv) tyrosine kinase inhibitors selected from the group consisting of erlotinib, geftinib, afatinib, lapatinib, and osimertinib;
- (v) cetuximab, either alone or combination with 5-FU, leucovorin, and irinotecan;
- (vi) panitumumab;
- (vii) regorafenib;
- (viii) trifluridine/tipiracil;
- and
- (ix) immune checkpoint inhibitors selected from the group consisting of nivolumab and ipilimumab.
15 more elements
Dependencies are inferred from the claim text.